177Lutetium-DOTA-octreotate therapy in progressive somatostatin receptor-expressing neuroendocrine neoplasms

被引：0
|
作者：
Delpassand, E. [1 ]
Mohammadali, H. [1 ]
Thamake, S. [2 ]
Broline, S. [1 ]
Ranganathan, D. [3 ]
Wagh, N. [3 ]
Tworowska, I. [2 ]
Delpassand, A. [2 ]
Puentes, J. [2 ]
机构：
[1] Excel Diagnost & Nucl Oncol Ctr, Houston, TX USA
[2] RadioMedix Inc, Houston, TX USA
[3] Radioisotope Therapy Amer RITA Fdn, Houston, TX USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
17
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA Octreotate for Somatostatin Receptor-expressing Neuroendocrine Tumors: The First US Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Erion, Jack
    Somone, Jim
    Wolfangel, Robert
    Wolin, Edward M.
    Espenan, Gregory D.
    [J]. PANCREAS, 2013, 42 (02) : 373 - 373
  • [2] Effect of Lutetium-177 Dota Octreotate Peptide Receptor Radionuclide Therapy in Patients With Advanced Neuroendocrine Tumors and Carcinoid Syndrome Refractory to Somatostatin Analogues
    Koffas, Apostolos
    Popat, Rickin
    Demetriou, George
    Quigley, Ann-Marie
    Navalkissoor, Shaunak
    Caplin, Martyn
    Toumpanakis, Christos
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S208 - S208
  • [3] Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
    Koffas, A.
    Popat, R.
    Dimitriou, G.
    Quigley, A. M.
    Navalkissoor, S.
    Caplin, M.
    Toumpanakis, C.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 81 - 81
  • [4] Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy
    De Silva, Madhawa K.
    Chan, David L. H.
    Bernard, Elizabeth J.
    Conner, Alice J.
    Mascall, Sophie L.
    Bailey, Dale L.
    Roach, Paul J.
    Clarke, Stephen J.
    Diakos, Connie I.
    Pavlakis, Nick
    Schembri, Geoff
    [J]. PANCREAS, 2024, 53 (07) : e560 - e565
  • [5] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors
    Abou Jokh Casas, E.
    Pombo Pasin, M. D.
    Pubul Nunez, V.
    Garrido Pumar, M.
    Blanco Freire, M. N.
    Cabezas, J.
    Cameselle, J.
    Berrios, M.
    Argibay, S.
    Ruibal Morell, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S598
  • [6] Treatment with 177Lutetium-DOTA-Tyr3-Octreotate in Patients with Neuroendocrine Tumors
    Granberg, D.
    Sandstrom, M.
    Sundin, A.
    Welin, S.
    Kozlovacki, G.
    Lindholm, D. P.
    Oberg, K.
    Eriksson, B.
    Grarske, U.
    [J]. NEUROENDOCRINOLOGY, 2011, 94 : 25 - 25
  • [7] Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment
    Hamiditabar, Mohammadali
    Ali, Muzammil
    Roys, Joseph
    Wolin, Edward M.
    O'Dorisio, Thomas M.
    Ranganathan, David
    Tworowska, Izabela
    Strosberg, Jonathan R.
    Delpassand, Ebrahim S.
    [J]. CLINICAL NUCLEAR MEDICINE, 2017, 42 (06) : 436 - 443
  • [8] Metabolic tumour volume (MTV) on 18-fluorodeoxyglucose positron emission tomography (FDGPET) as a prognostic marker of survival in patients with metastatic neuroendocrine neoplasms (mNENs) receiving 177Lutetium-DOTA-octreotate (Lutate)
    De Silva, Madhawa
    Chan, David
    Bernard, Elizabeth
    Connor, Alice
    Mascall, Sophie
    Bailey, Dale
    Roach, Paul
    Pavlakis, Nick
    Schembri, Geoffrey
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 118 - 118
  • [9] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Wolin, Edward M.
    Hamiditabar, Mohammadali
    Espenan, Gregory D.
    Erion, Jack L.
    O'Dorisio, Thomas M.
    Kvols, Larry K.
    Simon, Jaime
    Wolfangel, Robert
    Camp, Arthur
    Krenning, Eric P.
    Mojtahedi, Alireza
    [J]. PANCREAS, 2014, 43 (04) : 518 - 525
  • [10] [177Lu-DOTA0, Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy
    de Jong, M
    Breeman, WAP
    Bernard, BF
    Bakker, WH
    Schaar, M
    van Gameren, A
    Bugaj, JE
    Erion, J
    Schmidt, M
    Srinivasan, A
    Krenning, EP
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (05) : 628 - 633
12345